Does combination treatment including macitentan and/or selexipag improve non-invasive low-risk criteria in patients with pulmonary arterial hypertension?
Real-world combination therapy with macitentan and/or selexipag in PAH patients is associated with an increase in non-invasive low-risk criteria, suggesting disease stabilization over 12 months.
The INSPECTIO study supports the effectiveness of guideline-directed therapy and regular risk assessment to optimize treatment strategies in PAH. The increase in non-invasive low-risk criteria suggests a stabilization of disease over 12 months.
D'Alto et al. (2026) studied this question.